News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
281,886 Results
Type
Article (14913)
Company Profile (299)
Press Release (266668)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (79841)
Career Advice (163)
Deals (13340)
Drug Delivery (39)
Drug Development (50705)
Employer Resources (31)
FDA (5839)
Job Trends (5169)
News (145095)
Policy (10072)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (920)
Accelerated approval (19)
Adcomms (14)
Allergies (85)
Alliances (21762)
ALS (126)
Alzheimer's disease (1035)
Antibody-drug conjugate (ADC) (244)
Approvals (6035)
Artificial intelligence (267)
Autoimmune disease (119)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (101)
Biotechnology (230)
Bladder cancer (101)
Brain cancer (46)
Breast cancer (348)
Cancer (3163)
Cardiovascular disease (239)
Career advice (148)
Career pathing (8)
CAR-T (224)
CDC (5)
Cell therapy (577)
Cervical cancer (14)
Clinical research (43723)
Collaboration (1168)
Company closure (2)
Compensation (603)
Complete response letters (41)
COVID-19 (1101)
CRISPR (88)
C-suite (565)
Cystic fibrosis (112)
Data (4359)
Denatured (15)
Depression (93)
Diabetes (256)
Diagnostics (1383)
Digital health (13)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (196)
Drug pricing (48)
Drug shortages (3)
Duchenne muscular dystrophy (218)
Earnings (31686)
Editorial (27)
Employer branding (4)
Employer resources (29)
Events (51711)
Executive appointments (628)
FDA (7606)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (10)
Frontotemporal dementia (22)
Funding (991)
Gene editing (185)
Generative AI (22)
Gene therapy (497)
GLP-1 (507)
Government (1149)
Grass and pollen (3)
Guidances (166)
Healthcare (6613)
HIV (18)
Huntington's disease (43)
IgA nephropathy (75)
Immunology and inflammation (194)
Immuno-oncology (43)
Indications (71)
Infectious disease (1211)
Inflammatory bowel disease (157)
Inflation Reduction Act (10)
Influenza (40)
Intellectual property (169)
Interviews (18)
IPO (7347)
IRA (13)
Job creations (867)
Job search strategy (130)
JPM (40)
Kidney cancer (9)
Labor market (23)
Layoffs (243)
Leadership (10)
Legal (1401)
Liver cancer (41)
Longevity (11)
Lung cancer (425)
Lymphoma (251)
Machine learning (24)
Management (7)
Manufacturing (380)
MASH (132)
Medical device (2666)
Medtech (2675)
Mergers & acquisitions (6625)
Metabolic disorders (733)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (233)
Neuropsychiatric disorders (70)
Neuroscience (1965)
Neurotech (1)
NextGen: Class of 2026 (2034)
Non-profit (867)
Now hiring (31)
Obesity (333)
Opinion (125)
Ovarian cancer (132)
Pain (103)
Pancreatic cancer (165)
Parkinson's disease (232)
Partnered (12)
Patents (306)
Patient recruitment (345)
Peanut (44)
People (26689)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15492)
Phase 2 (20315)
Phase 3 (12831)
Pipeline (3354)
Policy (91)
Postmarket research (853)
Preclinical (6540)
Press Release (30)
Prostate cancer (147)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (661)
Real estate (1448)
Recruiting (12)
Regulatory (9922)
Reports (19)
Research institute (973)
Resumes & cover letters (19)
Rett syndrome (24)
RNA editing (21)
RSV (17)
Schizophrenia (125)
Series A (184)
Series B (140)
Service/supplier (1)
Sickle cell disease (78)
Special edition (18)
Spinal muscular atrophy (119)
Sponsored (15)
Startups (2006)
State (1)
Stomach cancer (5)
Supply chain (32)
Tariffs (18)
The Weekly (62)
Vaccines (340)
Venture capital (69)
Weight loss (174)
Women's health (26)
Worklife (2)
Date
Today (53)
Last 7 days (315)
Last 30 days (1169)
Last 365 days (17831)
2026 (1965)
2025 (18098)
2024 (20543)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23356)
2019 (16227)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7533)
2011 (7615)
2010 (7429)
Location
Africa (154)
Alabama (65)
Alaska (2)
Arizona (71)
Arkansas (5)
Asia (18274)
Australia (3114)
California (7141)
Canada (1857)
China (784)
Colorado (249)
Connecticut (255)
Delaware (237)
Europe (39210)
Florida (912)
Georgia (209)
Hawaii (2)
Idaho (17)
Illinois (398)
India (36)
Indiana (162)
Iowa (8)
Japan (228)
Kansas (80)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (740)
Massachusetts (5629)
Michigan (110)
Minnesota (250)
Mississippi (3)
Missouri (32)
Montana (16)
Nebraska (5)
Nevada (33)
New Hampshire (21)
New Jersey (1658)
New Mexico (13)
New York (1775)
North Carolina (837)
North Dakota (6)
Northern California (3516)
Ohio (180)
Oklahoma (11)
Oregon (24)
Pennsylvania (1287)
Puerto Rico (9)
Rhode Island (26)
South America (215)
South Carolina (9)
Southern California (2831)
Tennessee (40)
Texas (921)
United States (23536)
Utah (97)
Virginia (137)
Washington D.C. (37)
Washington State (593)
West Virginia (1)
Wisconsin (46)
281,886 Results for "anthos therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Novartis Bets Up to $3.1B to Buy Back Blood Thinner in Anthos Acquisition
Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.
February 11, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 Billion
February 11, 2025
·
7 min read
Business
Anthos Therapeutics Announces Appointment of Bill Meury as CEO
Anthos Therapeutics, Inc. today announced the appointment of Bill Meury as CEO and member of the board of directors.
April 22, 2024
·
11 min read
Press Releases
Blackstone Life Sciences and Anthos Therapeutics Announce Novartis has Completed the Acquisition of Anthos Therapeutics in a Deal Valued at up to $3.1B, with $925M Paid Upfront
April 4, 2025
·
4 min read
Press Releases
Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront
February 11, 2025
·
7 min read
Genetown
Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke
Anthos Therapeutics, Inc., a clinical-stage company developing innovative therapies for cardiovascular diseases, founded by Blackstone Life Sciences (BXLS), today provided an update on the transition of patients in the open-label extension (OLE) portion of the AZALEA-TIMI 71 study.
June 6, 2024
·
10 min read
Press Releases
Anthos Therapeutics Appoints Will Kane as President and Chief Commercial Officer and Venkat Ramanan as Chief Financial Officer
October 31, 2024
·
4 min read
Press Releases
Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk
March 31, 2025
·
9 min read
Press Releases
Anthos Therapeutics Appoints Mia Kelley as General Counsel and Laurel Ostrom as Chief Human Resources Officer
October 10, 2024
·
4 min read
Drug Development
Anthos Stops Mid-Stage Atrial Fibrillation Trial Due to ‘Unprecedented’ Efficacy
After evidence of “overwhelming reduction” in bleeding compared to Bayer and J&J’s Xarelto, Anthos Therapeutics has ended its Phase II atrial fibrillation study for abelacimab ahead of schedule.
September 18, 2023
·
2 min read
·
Tristan Manalac
1 of 28,189
Next
